ASPI - NASDAQ

ASP Isotopes Inc. Common Stock

ASPI·NASDAQ

$7.55

+5.6%

Basic MaterialsChemicals

ASP Isotopes Inc., a pre-commercial stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It develops Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company also Uranium-235, an isotope of uranium for carbon-free energy industry. ASP Isotopes Inc. was incorporated in 2021 and is based in Boca Raton, Florida.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$627.39M

EPS-2.1100

P/E Ratio-2.54

Earnings Date08/14/2026

512.88M

Assets

444%

3Y+4004.0%

5Y+7081.0%

10Y+7081.0%

249.98M

Total Liabilities

479%

3Y+9232.0%

5Y+21733.0%

10Y+21733.0%

262.90M

Total Equity

414%

3Y+2578.0%

5Y+4283.0%

10Y+4283.0%

ASP Isotopes Inc. Common Stock Funding & Solvency Profile

ASPI · NASDAQ

Current Assets

Cash & Cash Equivalents285.56M

Net Receivables51.71M

Inventory8.49M

Other Current Assets2.64M

Total Current Assets398 M

Non-Current Assets

Property, Plant & Equipment34.96M

Goodwill & Intangible Assets10.05M

Long-Term Investments49.00M

Other Non-Current Assets5.87M

Total Non-Current Assets90 M

Total Assets

512.88M

Financial Health Analysis

Current Ratio

12.18x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.95x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

365 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

78% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

ASP Isotopes Inc. Common Stock Balance Sheet

ASPI • NASDAQ

ASP Isotopes Inc. Common Stock Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	285.6M	61.9M	7.9M	2.4M	3M
Short-Term Investments	47.7M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	333.3M	61.9M	7.9M	2.4M	3M
Net Receivables	51.7M	734.5K	938.1K	0.0	0.0
Accounts Receivables	50.9M	706.9K	216.5K	0.0	0.0
Other Receivables	763K	27.6K	721.5K	0.0	0.0
Inventory	8.5M	65.7K	0.0	0.0	0.0
Prepaids	2M	0.0	0.0	0.0	267.6K
Other Current Assets	2.6M	3.1M	1.7M	913K	0.0
Total Current Assets	398.1M	65.7M	10.5M	3.3M	3.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	35M	23.5M	12M	9.1M	3.9M
Goodwill	8.6M	3.2M	3.3M	0.0	0.0
Intangible Assets	1.5M	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	10M	3.2M	3.3M	0.0	0.0
Long-Term Investments	49M	0.0	0.0	0.0	0.0
Tax Assets	14.9M	5.8M	0.0	0.0	0.0
Other Non-Current Assets	5.9M	-3.8M	4.4M	139.6K	0.0
Total Non-Current Assets	114.7M	28.6M	19.7M	9.2M	3.9M
Total Assets	512.9M	94.3M	30.2M	12.5M	7.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.8M	1M	1.1M	1.4M	59.7K
Accounts Payable	5.8M	1M	1.1M	1.4M	59.7K
Accrued Expenses	3.6M	2.3M	845.3K	361.2K	0.0
Short Term Debt	13.6M	939.1K	470.4K	33.9K	85K
Capital Lease Obligations (Current)	0.0	683.5K	398.5K	45.9K	0.0
Deferred Revenue	882K	882K	882K	0.0	0.0
Other Current Liabilities	8.8M	1.3M	2M	140.5K	158.7K
Total Current Liabilities	32.7M	7.1M	5.7M	1.9M	303.4K
NON-CURRENT LIABILITIES
Long Term Debt	200.8M	34.9M	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	15M	0.0	110.6K	0.0	0.0
Other Non-Current Liabilities	0.0	5.7M	4.3M	0.0	0.0
Total Non-Current Liabilities	217.3M	41.9M	5.7M	742.4K	841.6K
Other Liabilities	0.0	-5.7M	0.0	0.0	0.0
Capital Lease Obligations	1.5M	1.9M	1.7M	788.3K	841.6K
Total Liabilities	250M	43.2M	11.4M	2.7M	1.1M
SHAREHOLDERS' EQUITY
Common Stock	1.1M	720.7K	489.2K	359.1K	206.5K
Additional Paid-In Capital	431.8M	105.5M	40.6M	16.8M	8.4M
Retained Earnings	-231.3M	-56.2M	-23.8M	-7.6M	-2.6M
Accumulated Other Comprehensive Income/Loss	2.5M	-2.2M	-921K	255K	18.7K
Total Stockholders' Equity	204.2M	47.9M	16.3M	9.8M	6M
Total Equity	262.9M	51.2M	18.8M	9.8M	6M
Minority Interest	58.7M	3.3M	2.5M	0.0	0.0
SUMMARY
Total Liabilities & Equity	512.9M	94.3M	30.2M	12.5M	7.1M
Total Investments	96.7M	0.0	0.0	0.0	0.0
Total Debt	216M	37.7M	2.1M	822.2K	926.6K
Net Debt	-69.6M	-24.1M	-5.8M	-1.6M	-2M
Shares Outstanding	91,955,293	91,955,293	91,955,293	91,955,293	91,955,293

SEC Filings

ASPI - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 26, 2026	May 26, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 20, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 20, 2026	May 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	April 30, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	April 13, 2026	April 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 10, 2026	April 10, 2026	2026	View Filing
10-K 10-K 2025 FY FY	April 10, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 24, 2026	March 24, 2026	2026	View Filing

Showing 1 to 10 of 137 filings

Related Guides

Blog Categories

Continue your ASPI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.